Abstract:
Introduction. The preservation of perinatal biological materials - umbilical cord blood, umbilical cord
tissue, and placental tissue - has become one of the most important developments in modern preventive
and regenerative medicine. These tissues represent a unique biological resource rich in hematopoietic
stem cells (HSCs) and mesenchymal stem cells (MSCs). Compared with adult stem cells, perinatal
stem cells demonstrate higher proliferative potential, broader differentiation capacity, and lower
immunogenicity. Since the first successful umbilical cord blood transplantation in 1988, the clinical
field of stem cell transplantation has expanded rapidly. To date, more than 40,000 cord blood
transplants have been performed worldwide. Beyond hematological diseases, increasing scientific
attention is focused on the role of perinatal stem cells in regenerative medicine, tissue engineering, and
advanced transplantation technologies. Their biological characteristics make them a promising
platform for future personalized therapeutic strategies.
Materials and Methods. This analytical review was conducted using systematic literature searches in
major biomedical databases including PubMed and ClinicalTrials.gov. Key search terms included:
umbilical cord blood banking, perinatal stem cells, mesenchymal stem cells, regenerative medicine,
and tissue transplantation. More than 600 scientific publications were initially identified. Following
relevance screening and quality assessment, 12 peer‑reviewed clinical studies and experimental reports
were selected for detailed analysis. The review focused on clinically validated therapeutic applications
of perinatal stem cells as well as emerging experimental approaches in regenerative transplantation
and tissue bioengineering.
Results. Hematopoietic stem cells obtained from umbilical cord blood are currently used in
evidence‑based clinical practice for the treatment of more than 80 diseases, including leukemias,
lymphomas, inherited metabolic disorders, and immune deficiencies. Mesenchymal stem cells derived
from umbilical cord tissue and placenta demonstrate strong regenerative, anti‑inflammatory, and
immunomodulatory properties. These characteristics make MSCs particularly attractive for
regenerative therapeutic strategies. Recent experimental clinical studies suggest potential applications
of perinatal stem cells in neurological injuries, including spinal cord trauma, where stem cells may
contribute to neuronal repair and functional recovery. In orthopedic and traumatology practice,
MSC‑based therapies are increasingly investigated for enhancing tissue regeneration following joint
replacement procedures and severe musculoskeletal injuries. At the same time, regenerative medicine
is moving toward organ bioengineering. Researchers at Tel Aviv University and Sheba Medical Center
have successfully developed human kidney organoids derived from stem cells that remained stable for
up to 34 weeks under laboratory conditions and demonstrated developmental characteristics similar to
fetal kidney tissue.
Conclusions. Perinatal stem cell banking represents a strategically important biomedical resource
capable of expanding the therapeutic potential of modern cell and tissue transplantation. The
integration of cryopreserved perinatal stem cells into regenerative medicine, trauma recovery
protocols, and organ bioengineering may significantly transform future treatment strategies for severe
diseases and complex injuries. As regenerative technologies continue to evolve, access to high‑quality
perinatal stem cells is likely to become a decisive factor shaping the future of personalized medicine
and transplantation science.
